Showing 1141-1150 of 1484 results for "".
- AOA Announces 2019 National Optometry Hall of Fame Inducteeshttps://modernod.com/news/aoa-announces-2019-national-optometry-hall-of-fame-inductees/2476443/The American Optometric Association has announced the four ODs who will be inducted into the National Optometry Hall of Fame in 2019. This year’s inductees are: Murray Fingeret, OD; Donald Jarnagin, OD; Michael Mittelman, OD; and Glen Steele, OD.
- FDA Grants Atia Vision Approval to Begin US Clinical Trial of OmniVu Lens System in Patients with Cataractshttps://modernod.com/news/fda-grants-atia-vision-approval-to-begin-us-clinical-trial-of-omnivu-lens-system-in-patients-with-cataracts/2482811/Atia Vision has received Investigational Device Exemption (IDE) approval from the FDA to begin a traditional feasibility clinical study of its OmniVu Lens System. This novel IOL is designed to restore dynamic range of vision following catar
- FDA Accepts Iveric Bio's NDA and Grants Priority Review for Geographic Atrophy Drug Candidatehttps://modernod.com/news/fda-accepts-iveric-bios-nda-and-grants-priority-review-for-geographic-atrophy-drug-candidate/2481418/Iveric bio announced that the FDA has completed its filing review and accepted the company’s new drug application (NDA) for avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degen
- Research to Prevent Blindness and the American Academy of Ophthalmology Award New Research Grants to Improve Eye Carehttps://modernod.com/news/research-to-prevent-blindness-and-the-american-academy-of-ophthalmology-award-new-research-grants-to-improve-eye-care/2481025/The American Academy of Ophthalmology and Research to Prevent Blindness (RPB) announced the 2022 recipients of the RPB/AAO Award for IRIS Registry Research. The researchers will use the IRIS Registry—the nation’s first and largest comprehensive eye disease clinical registry—to c
- Ocuphire Granted New US Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabeticshttps://modernod.com/news/ocuphire-granted-new-us-patent-for-late-stage-oral-drug-candidate-apx3330-for-use-in-diabetics/2480941/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued a new patent extending expiry and broadening coverage of the company’s late-stage oral product candidate, APX3330, for diabetic eye disease. In addition, a new publication supporting the nov
- American Academy of Optometry announces the 2022 ARVO Student Travel Fellowship Grant Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-the-2022-arvo-student-travel-fellowship-grant-recipients/2480811/
- Innovega Grants Commercial License of its Next-Generation Display Eyewear to Global Supplierhttps://modernod.com/news/innovega-grants-commercial-license-of-its-next-generation-display-eyewear-to-global-supplier/2480728/Innovega finalized a definitive licensing agreement with one of the world's leading providers of assistive technology for the visually impaired, including the legally blind. This is the first commercial licensing agreement for Innovega’s next-generation display eyewear
- Kiora Pharmaceuticals Granted Orphan Drug Designation for KIO-301, an Investigational Drug for the Treatment of Retinitis Pigmentosa (RP)https://modernod.com/news/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp/2480706/Kiora Pharmaceuticals has received orphan drug designation from the FDA for its investigational treatment of retinitis pigmentosa, KIO-301. Kiora expects to initiate clinical trials of KIO-301 in Q3 2022. Orphan drug designation provides for facilitated development discussions with the FDA,
- Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate Nyxol Including for the Treatment of Presbyopiahttps://modernod.com/news/ocuphire-granted-two-new-us-patents-covering-late-stage-drug-candidate-nyxol-including-for-the-treatment-of-presbyopia/2479225/Ocuphire Pharma announced that the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine mesylate). Both patents are directed to categories of subject matter eligible for listing in the U.S. FDA Orange Boo
- States ‘Need More Supply’ of COVID-19 Vaccine Amid Push to Grant More Shotshttps://modernod.com/news/states-need-more-supply-of-covid-19-vaccine-amid-push-to-grant-more-shots/2478827/Several states told a congressional panel Tuesday that they have the capacity to dole out thousands more vaccines than they have been getting from the federal government, according to a FierceHealthcare